Knight Therapeutics Inc. (OTCMKTS:KHTRF) Sees Large Decrease in Short Interest

Knight Therapeutics Inc. (OTCMKTS:KHTRF) saw a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 317,034 shares, a decline of 35.2% from the May 31st total of 489,147 shares. Based on an average daily trading volume, of 24,638 shares, the days-to-cover ratio is currently 12.9 days.

Analyst Ratings Changes

Separately, Royal Bank Of Canada restated an “outperform” rating on shares of Knight Therapeutics in a report on Friday, May 8th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy”.

Knight Therapeutics Price Performance

OTCMKTS:KHTRF remained flat at $6.91 during mid-day trading on Friday. 1,010 shares of the company traded hands, compared to its average volume of 8,869. Knight Therapeutics has a 1-year low of $4.07 and a 1-year high of $7.40. The company has a 50 day moving average price of $6.21 and a two-hundred day moving average price of $5.18.

Knight Therapeutics Company Profile

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.